| A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA) (NCT07742215) | Biocad | 2026-06-15 |
| A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis (NCT07321093) | Biocad | 2025-11-01 |
| Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis (NCT07080034) | Biocad | 2025-08-14 |
| Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease (NCT07078994) | Biocad | 2025-08-14 |
| Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus (NCT07136389) | Biocad | 2025-03-27 |
| A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects (NCT07181694) | Biocad | 2025-03-12 |
| An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma (NCT06668792) | Biocad | 2024-12-26 |
| An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B (NCT06700096) | Biocad | 2024-11-07 |
| Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis (NCT06640517) | Biocad | 2024-08-08 |
| BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer (NCT07108309) | Biocad | 2024-07-15 |
| Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy Subjects (NCT06715540) | Biocad | 2024-03-29 |
| Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin (NCT06640530) | Biocad | 2024-03-21 |
| Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA) (NCT06333210) | Biocad | 2023-12-25 |
| A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma (NCT06296121) | Biocad | 2023-12-21 |
| A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin (NCT06112808) | Biocad | 2023-05-29 |
| A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects (NCT05974969) | Biocad | 2023-05-17 |
| Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN) (NCT06120582) | Biocad | 2023-05-02 |
| Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL) (NCT05747261) | Biocad | 2023-02-02 |
| Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer (NCT05802225) | Biocad | 2023-01-30 |
| Clinical Study of Divozilimab in Patients With Systemic Scleroderma (NCT05726630) | Biocad | 2022-12-26 |
| Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE) (NCT05730699) | Biocad | 2022-12-12 |
| A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis (NCT05800327) | Biocad | 2022-12-07 |
| A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers (NCT05738993) | Biocad | 2022-08-08 |
| A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma (NCT05732805) | Biocad | 2022-08-02 |
| Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma (NCT05986331) | Biocad | 2022-07-18 |
| An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD (NCT06987851) | Biocad | 2022-03-22 |
| Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma (NCT05783882) | Biocad | 2022-02-01 |
| Phase 1 Study of BCD-245 in Subjects With Neuroblastoma (NCT05782959) | Biocad | 2021-11-29 |
| Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19) (NCT05037188) | Biocad | 2021-08-10 |
| An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis (NCT05385744) | Biocad | 2021-04-05 |
| Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies (NCT05739006) | Biocad | 2021-02-08 |
| Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy Volunteers (NCT05407779) | Biocad | 2021-01-22 |
| DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs (NCT04811443) | Biocad | 2021-01-12 |
| A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19 (NCT04397562) | Biocad | 2020-04-29 |
| An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2/NOCTURN (NCT06987864) | Biocad | 2020-04-13 |
| Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis (NCT04227366) | Biocad | 2019-11-19 |
| Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA) (NCT03912415) | Biocad | 2019-10-01 |
| Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma (NCT03913923) | Biocad | 2019-07-01 |
| Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis (NCT04056897) | Biocad | 2019-06-07 |
| Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC (NCT03912389) | Biocad | 2019-06-01 |
| Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria (NCT04060264) | Biocad | 2019-04-04 |
| First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy Subjects (NCT03912441) | Biocad | 2019-01-30 |
| Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA) (NCT03912402) | Biocad | 2018-12-25 |
| Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® (NCT04027803) | Biocad | 2018-09-21 |
| Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis (NCT03598751) | Biocad | 2018-07-25 |
| Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis (NCT03476993) | Biocad | 2018-04-27 |
| Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis (NCT03551275) | Biocad | 2018-02-22 |
| International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing Spondylitis (NCT03447704) | Biocad | 2018-02-09 |
| The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis (NCT03455842) | Biocad | 2018-02-01 |
| An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis (NCT03390101) | Biocad | 2017-12-26 |
| A Study of BCD-135 in Patients With Advanced Solid Tumors (NCT03464032) | Biocad | 2017-10-31 |
| Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis (NCT03519243) | Biocad | 2017-10-24 |
| Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma (NCT03472027) | Biocad | 2017-10-02 |
| Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS) (NCT03288870) | Biocad | 2017-09-19 |